The distribution and pathogenic risk of non‐9‐valent vaccine covered HPV subtypes in cervical lesions. (3rd January 2022)

• Record Type: Journal Article
• Authors: Ma, Mingjun; Zhu, Jingfen; Yang, Yongbin; Wang, Xiaoyun; Jin, Yubiao; Zhang, Jiawen; Wu, Sufang
• Is Part Of: Cancer medicine. Volume 11:Number 6(2022)
• Page Start: 1542
• Page End: 1552
• Publication Date: 2022-01-03
• Subjects: cervical lesions -- CIN -- HPV genotypes -- HPV vaccine -- risk factors; 616.994005
• DOI: 10.1002/cam4.4532
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Human papillomavirus (HPV) infection is the main cause of female precancerous lesions and cervical cancer. The development and application of HPV prophylactic vaccines have been recognized as a major effective intervention for the control of cervical lesions. However, the infection rate and clinical characters of non‐9‐valent vaccine covered HPV subtypes are still worth studying. In this retrospective study, we included patients diagnosed and treated in the Department of Gynecology of Shanghai General Hospital between January 2017 and February 2021. The clinical features of non‐9‐valent vaccine covered HPV subtypes were explored in 2179 patients who have normal results, 338 patients with cervical intraepithelial neoplasia 1 (CIN1), and 153 patients with ≥CIN2. Univariate analysis showed that compared to the normal cervix group, age ≥50, pregnancy ≥5, delivery ≥3, menopause, no condom use, and cervical transformation zone type III were risk factors for CIN1 or ≥CIN2 ( p < 0.05). Thirty‐one percent of CIN1 and 26% of ≥CIN2 were attributed to HPV51, HPV53, HPV56, and HPV68. Multivariate analysis revealed that HPV53, HPV81, age, menopause, cervical transformation area and involved glands were independent risk factors for ≥CIN2 group compared to the CIN1 group ( p < 0.05). Additionally, among the 14 non‐9‐valent vaccine covered HPV subtypes, the infection rates of HPV53, 56, 51, and 68 were higher in this study. In conclusion, our study demonstrated the distribution and pathogenic risk of non‐9‐valent vaccine covered HPV subtypes in cervical lesions. These findings might supply a foundation for optimizing cervical cancer prevention in the post‐vaccine era. Abstract : We identified the most non‐9‐valent vaccine covered carcinogenic HPV types, so as to provides a basis for further optimizing screening methods and eliminating cervical cancer in the post‐vaccine era.